Although immune checkpoint inhibitors, including anti-PD-1 antibodies (nivolumab, pembrolizumab), anti-PD-L1 antibodies (atezolizumab, durvalumab, avelumab), and anti-CTLA-4 antibodies (ipilimumab, tremelimumab), have demonstrated efficacy in many cancers, no favorable clinical responses have been reported in patients with CRC [58]. The gene discussed is CD274; the disease is colorectal carcinoma.